NCT04000425 is a clinical trial of AVENIO ctDNA surveillance kit in Gastric Cancer, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT04000425?

NCT04000425 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT04000425?

Interventions in NCT04000425: AVENIO ctDNA surveillance kit.

What condition does NCT04000425 study?

NCT04000425 studies Gastric Cancer.

Is NCT04000425 still recruiting?

NCT04000425 is currently status unknown. Last updated 27 June 2019.

Last reviewed 2019-06-27 · How we verify

NCT04000425

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Potential Clinical Utilities of Circulating Tumor DNA in Gastric Cancer

Status unknown Last updated 27 June 2019

What this trial tests

trial testing AVENIO ctDNA surveillance kit in Gastric Cancer in 55 participants. Status unknown.

Timeline

1 December 2018

Primary endpoint
1 March 2021

31 May 2021

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	55
Start date	1 December 2018
Primary completion	1 March 2021
Estimated completion	31 May 2021
Sites	1 location across China

Drugs / interventions tested

AVENIO ctDNA surveillance kit

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 75, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate the potential clinical utility of ctDNA in the field of gastric cancer treatment,especially the usage of an indicator of MRD(minimal residual disease) in post radical gastrectomy patients. The primary purpose of this trial is to demonstrate if the postoperative ctDNA analysis could be used as an indicator of MRD or adjuvant chemotherapy response in advanced gastric cancer after radical gastrectomy.The second purpose is to describe the profile of ctDNA in gastric cancer.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Liquid biopsy in gastric cancer: predictive and prognostic biomarkers.
Zhang Z, Wu H, Chong W, Shang L, et al · · 2022 · cited 84× · PMID 36302755 · DOI 10.1038/s41419-022-05350-2
The Emerging Role of Liquid Biopsy in Gastric Cancer.
Lengyel CG, Hussain S, Trapani D, El Bairi K, et al · · 2021 · cited 35× · PMID 34068319 · DOI 10.3390/jcm10102108
Clinical applications and perspectives of circulating tumor DNA in gastric cancer.
Li JH, Zhang DY, Zhu JM, Dong L. · · 2024 · cited 14× · PMID 38184573 · DOI 10.1186/s12935-024-03209-4
Current and emerging applications of liquid biopsy in pan-cancer.
Wang W, He Y, Yang F, Chen K. · · 2023 · cited 12× · PMID 37315508 · DOI 10.1016/j.tranon.2023.101720
Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, et al · · 2025 · cited 6× · PMID 39920551 · DOI 10.1007/s10147-024-02683-0
Blood-Based Surveillance Biomarkers for Gastroesophageal Cancers.
Dadgar N, Anees M, Sherry C, Park HY, et al · · 2025 · cited 2× · PMID 41228346 · DOI 10.3390/cancers17213552

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04000425 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 27 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04000425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing